Product Data Sheet

Dasatinib N-oxide

Cat. No.: HY-133794 CAS No.: 910297-52-8 Molecular Formula: $\mathsf{C_{22}H_{26}CIN_{7}O_{3}S}$

Molecular Weight: 504

Target: **Drug Metabolite**

Pathway: Metabolic Enzyme/Protease 4°C, protect from light Storage:

* In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

SOLVENT & SOLUBILITY

In Vitro

DMSO: 8.33 mg/mL (16.53 mM; ultrasonic and warming and heat to 60°C)

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9841 mL	9.9206 mL	19.8413 mL
	5 mM	0.3968 mL	1.9841 mL	3.9683 mL
	10 mM	0.1984 mL	0.9921 mL	1.9841 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.83 mg/mL (1.65 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.83 mg/mL (1.65 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.83 mg/mL (1.65 mM); Clear solution

BIOLOGICAL ACTIVITY

Description Dasatinib N-oxide is a minor metabolite of Dasatinib. Dasatinib is a potent and orally active dual Src/Bcr-Abl inhibitor^{[1][2]}.

In Vivo Dasatinib N-oxide is the pharmacologically active metabolite after oral administration [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Christopher LJ, et, al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab Dispos. 2008 Jul;36(7):1357-64.

	imultaneous determination of the c study. J Pharm Biomed Anal. 20	e anti-leukemic agent dasatinib and two p 12	harmacologically active metabolites
Caution: Product has n	ot been fully validated for me	edical applications. For research use o	only.
Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpress.	com
	. Deer Park Dr, Suite Q, Monmo		

Page 2 of 2 www.MedChemExpress.com